About
AD-Venture is a groundbreaking joint venture formed
by three innovative companies:
StableBody Technologies | Quine Biologics | 20/15 Visioneers
This strategic collaboration leverages the unique strengths of each partner to
redefine possibilities in computational biology, advanced biologics design, and ideation.
AD-Venture’s mission is to harness human intuition, scientific rigor, and artificial intelligence (AI) to develop novel biological sequences with superior stability, functionality, and scalability.
Recognized for its innovative approaches to gene editing and synthetic biology, Quine’s contributions include advanced platforms for precision molecular engineering.
Renowned for its proprietary methods to enhance protein stability in extreme conditions, StableBody brings unparalleled expertise in biologics design and stability.
Specializing in scientific informatics, scientific software development and human-centered AI systems, 20/15 Visioneers adds critical computational and predictive modeling capabilities to the joint venture. Given its 30 Years of advanced end to end drug discovery and development experience, 20/15 Visioneers brings the project management and marketing and communications to the project.
Ad-
Venture
.bio
Our Advantage
Accelerating Discovery
Use machine learning models to predict and design novel proteins, enzymes, and genetic sequences with high precision.
Enhancing Stability and Performance:
Develop biological sequences optimized for stability in extreme environments, including high temperatures and low pH.
Customizable Solutions:
Collaborate with industry partners to co-develop solutions tailored to specific applications, from biopharmaceuticals to sustainable industrial processes.
Fostering Collaboration:
Build a robust ecosystem of researchers, institutions, and enterprises to drive innovation and ensure rapid deployment of technologies.
Key Innovations
AD-Venture operates at the intersection of biology, chemistry, and
artificial intelligence, delivering the following innovations:
Proprietary Computational Algorithms
Advanced algorithms that simulate molecular interactions to predict optimal biological configurations.
High-Throughput
Screening Platforms
Integration of AI-powered screening systems to rapidly identify high-potential biological candidates.
StableBody
Technology
AffiBio, a proprietary platform for engineering robust proteins and enzymes, ensuring functionality under extreme conditions.
Precision Editing
Tools
Gene-editing platforms for designing bespoke genetic sequences with unparalleled specificity and efficiency.
Human-AI
Collaboration Models
Frameworks that combine the intuition of human experts with the computational power of AI for accelerated decision-making
Impact
Healthcare
-
Development of next-generation biologics for chronic and rare diseases.
-
Design of highly stable therapeutic proteins and enzymes.
-
Precision medicine applications, including personalized therapeutics and diagnostics.
Industrial Biotechnology
-
Creation of enzymes for sustainable manufacturing processes.
-
Bioplastics and other eco-friendly materials engineered for robustness and longevity.
Environmental Solutions
-
Engineering of microbes for bioremediation and carbon capture.
-
Development of sustainable agricultural solutions to enhance crop resilience.
Our leadership team exemplifies the power of collaboration, uniting unique strengths to achieve what no single organization could accomplish alone. Together, they lead with vision and innovation, delivering transformative solutions through unparalleled synergy.
Leadership
Contact
